KP-483 / Kaken Pharma - LARVOL DELTA

Preclinical investigations and first-in-human phase I trial of KP-483 in solid tumors: Safety, antitumor activity, and preliminary efficacy. (ASCO 2026) - P | "KP-483 is a potent EP4 antagonist that exerts antitumor effects through modulation of the tumor immune microenvironment. Given its favorable safety and pharmacokinetic profiles, KP-483 represents a promising EP4 receptor–targeted therapeutic strategy with potential for combination with immune checkpoint inhibitors."

First-in-human • P1 data • Preclinical • Hematological Disorders • Oncology • Solid Tumor • CD163 • CD8